An international alliance, the APLC has established a large international patient cohort, currently the third largest in the world. With 1671 participants and over 6500 items of data, the APLC is investigating the validation of a new disease target, the Lupus Low Disease Activity State (LLDAS). This study has been in progress for more than three years and is likely to continue for the next five years.

Twelve institutions from nine
countries in the Asia-Pacific region (Australia, China, Indonesia, Japan,
Malaysia, Philippines, Singapore, Taiwan and Thailand) were represented at the meeting last month.